MILAN, ITALY--(Marketwire - September 26, 2007) - Recordati announced that it has successfully completed the double-blind portion of the phase III study of silodosin, an alpha-blocker for the treatment of signs and symptoms of benign prostatic hyperplasia (BPH) licensed from Kissei. The trial was conducted in 11 European countries with 1128 patients (977 randomized) enrolled in 70 clinical centres.
